Development and stability studies of novel liposomal vancomycin formulations

Area of Science:

• Pharmacology
• Drug Delivery
• Nanotechnology

Background:

• Vancomycin is a gold standard for MRSA pneumonia but has limitations including slow action, poor lung penetration, and low intracellular macrophage penetration.
• Liposomal encapsulation is a strategy to enhance antimicrobial delivery to infected tissues and macrophages, improving pharmacodynamics and pharmacokinetics while reducing toxicity.

Purpose of the Study:

• To prepare and characterize conventional and PEGylated liposomal vancomycin formulations.
• To evaluate the efficacy of these liposomal formulations in targeting intracellular MRSA and assess their pharmacokinetic and biodistribution profiles.

Main Methods:

• Vancomycin was encapsulated into conventional and PEGylated liposomes using various preparation methods.
• The dehydration-rehydration method was identified as optimal.
• Formulations were characterized for particle size, encapsulation efficiency, and physical stability at 4°C for 3 months.

Main Results:

• Both conventional and PEGylated liposomal vancomycin formulations were successfully prepared with narrow particle size distribution.
• Encapsulation efficiencies were 9 ± 2% and 12 ± 3% for conventional and PEGylated liposomes, respectively.
• Both formulations demonstrated stability at 4°C for 3 months and were suitable for further in vitro and in vivo studies.

Conclusions:

• Liposomal vancomycin, particularly PEGylated formulations, presents a viable strategy to enhance vancomycin delivery for MRSA pneumonia.
• These targeted formulations show potential for improved intracellular killing of MRSA and optimized pharmacokinetic profiles.
• Further investigation into these liposomal vancomycin formulations could lead to more effective treatments for challenging bacterial infections.